INTERIM ANALYSIS OF THE GCC1949 PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS

被引：0
|
作者：
Johnson, Theodore S. [1 ,2 ]
Pacholczyk, Rafal [1 ]
Aguilera, Dolly [3 ,4 ]
Berrong, Zuzana [1 ]
Castellino, Robert C. [3 ,4 ]
Chi, Susan [5 ]
Creager, Julianne [6 ]
Eaton, Bree R. [7 ,8 ]
Fangusaro, Jason R. [3 ,4 ]
Huang, Chenbin [9 ,10 ]
Hummel, Trent [11 ]
Ingerski, Lisa [3 ,4 ]
Kennedy, Eugene P. [6 ]
Ring, Eric [1 ]
Sadek, Ramses F. [1 ,12 ]
Satpathy, Sarthak [9 ,10 ]
Schniederjan, Matthew [13 ,14 ]
Thomas, Beena E. [9 ]
Yeo, Kee Kiat [5 ]
Bhasin, Manoj [3 ,4 ,10 ]
MacDonald, Tobey J. [3 ,4 ]
Munn, David H. [1 ,2 ]
机构：
[1] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA
[2] Augusta Univ, Dept Pediat, Augusta, GA USA
[3] Emory Univ, Aflac Canc & Blood Disorders Ctr, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA
[4] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA
[5] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA
[6] Lumos Pharma Inc, Austin, TX USA
[7] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA
[8] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[9] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA
[10] Emory Univ, Sch Med, Dept Biomed Informat, Atlanta, GA USA
[11] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA
[12] Augusta Univ, Dept Populat Hlth Sci, Augusta, GA USA
[13] Emory Univ, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA
[14] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
来源：
NEURO-ONCOLOGY | 2023年 / 25卷
关键词：
D O I：
10.1093/neuonc/noad073.177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
HGG-28
引用
收藏
页数：1
相关论文
共 22 条
  • [1] PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH CHILDHOOD BRAIN CANCER: INTERIM ANALYSIS OF THE GCC1949 STUDY (NCT04049669)
    Johnson, Theodore S.
    Pacholczyk, Rafal
    Ring, Eric K.
    Aguilera, Dolly
    Castellino, Robert C.
    Fangusaro, Jason R.
    Eaton, Bree R.
    Chi, Susan
    Yeo, Kee Kiat
    Hummel, Trent R.
    Berrong, Zuzana
    Creager, Julianne
    Ingerski, Lisa
    Schniederjan, Matthew
    Huang, Chenbin
    Satpathy, Sarthak
    Thomas, Beena E.
    Sadek, Ramses F.
    Kennedy, Eugene P.
    Bhasin, Manoj K.
    Macdonald, Tobey J.
    Munn, David H.
    NEURO-ONCOLOGY, 2024, 26
  • [2] Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial
    Johnson, Theodore S.
    MacDonald, Tobey J.
    Pacholczyk, Rafal
    Aguilera, Dolly
    Al-Basheer, Ahmad
    Bajaj, Manish
    Bandopadhayay, Pratiti
    Berrong, Zuzana
    Bouffet, Eric
    Castellino, Robert C.
    Dorris, Kathleen
    Eaton, Bree R.
    Esiashvili, Natia
    Fangusaro, Jason R.
    Foreman, Nicholas
    Fridlyand, Diana
    Giller, Cole
    Heger, Ian M.
    Huang, Chenbin
    Kadom, Nadja
    Kennedy, Eugene P.
    Manoharan, Neevika
    Martin, William
    McDonough, Colleen
    Parker, Rebecca S.
    Ramaswamy, Vijay
    Ring, Eric
    Rojiani, Amyn
    Sadek, Ramses F.
    Satpathy, Sarthak
    Schniederjan, Matthew
    Smith, Amy
    Smith, Christopher
    Thomas, Beena E.
    Vaizer, Rachel
    Yeo, Kee Kiat
    Bhasin, Manoj K.
    Munn, David H.
    NEURO-ONCOLOGY, 2024, 26 (02) : 348 - 361
  • [3] FIRST-IN-CHILDREN PHASE 1 TRIAL OF INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS: ANALYSIS OF SAFETY, TOLERABILITY, AND 5-YEAR OUTCOME
    Johnson, Theodore
    Pacholczyk, Rafal
    Aguilera, Dolly
    Al-Basheer, Ahmad
    Bajaj, Manish
    Bandopadhayay, Pratiti
    Berrong, Zuzana
    Bouffet, Eric
    Castellino, Robert
    Dorris, Kathleen
    Eaton, Bree
    Esiashvili, Natia
    Foreman, Nicholas
    Fridlyand, Diana
    Giller, Cole
    Heger, Ian
    Kadom, Nadja
    Kennedy, Eugene
    Manoharan, Neevika
    Martin, William
    McDonough, Colleen
    Parker, Rebecca
    Ramaswamy, Vijay
    Ring, Eric
    Rojiani, Amyn
    Sadek, Ramses
    Smith, Amy
    Smith, Chris
    Vaizer, Rachel
    Yeo, Kee Kiat
    MacDonald, Tobey
    Munn, David
    NEURO-ONCOLOGY, 2022, 24 : 68 - 68
  • [4] Effect of indoximod-based chemo-immunotherapy in patients with pediatric brain tumors on activation and clonal proliferation of a circulating population of early non-exhausted stem-like CD8+T cells whose on-treatment expansion is predictive of long-term outcome.
    Pacholczyk, Rafal
    Satpathy, Sarthak
    Berrong, Zuzana
    Chien, Franklin
    Huang, Chenbin
    Sadek, Ramses F.
    Thomas, Beena E.
    Smith, Christopher
    MacDonald, Tobey J.
    Kennedy, Eugene Paul
    Johnson, Theodore S.
    Bhasin, Manoj K.
    Munn, David H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Repurposing ibrutinib for chemo-immunotherapy in a phase 1b study of ibrutinib with indoximod plus metronomic cyclophosphamide and etoposide for patients with childhood brain cancer.
    Johnson, Theodore S.
    Pacholczyk, Rafal
    Satpathy, Sarthak
    Berrong, Zuzana
    Creager, Julianne
    Huang, Chenbin
    Kennedy, Eugene Paul
    Ring, Eric K.
    Sadek, Ramses F.
    Thomas, Beena E.
    Bhasin, Manoj K.
    Munn, David H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma
    Zakharia, Yousef
    McWilliams, Robert
    Shaheen, Monaster
    Grossman, Kenneth
    Drabick, Joseph
    Milhem, Mohammed
    Rixie, Olivier
    Khleif, Samir
    Lott, Ryan
    Kennedy, Eugene
    Munn, David
    Vahanian, Nicholas
    Link, Charles
    CANCER RESEARCH, 2017, 77
  • [7] INTERIM ANALYSIS OF PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY INHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS
    Zakharia, Yousef
    Munn, David
    Link, Charles
    Vahanian, Nicholas
    Kennedy, Eugene
    NEURO-ONCOLOGY, 2016, 18 : 13 - 14
  • [8] Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trial
    King, Amanda L.
    Roche, Kayla N.
    Leeper, Heather E.
    Vera, Elizabeth
    Mendoza, Tito
    Mentges, Kelly
    Acquaye-Mallory, Alvina A.
    Adegbesan, Kendra A.
    Boris, Lisa
    Burton, Eric
    Choi, Anna
    Grajkowska, Ewa
    Kunst, Tricia
    Levine, Jason
    Lollo, Nicole
    Miller, Hope
    Panzer, Marissa
    Penas-Prado, Marta
    Pillai, Valentina
    Polskin, Lily
    Reyes, Jennifer
    Sahebjam, Solmaz
    Stockdill, Macy L.
    Theeler, Brett J.
    Wu, Jing
    Gilbert, Mark R.
    Armstrong, Terri S.
    JOURNAL OF NEURO-ONCOLOGY, 2023, 162 (01) : 137 - 145
  • [9] Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trial
    Amanda L. King
    Kayla N. Roche
    Heather E. Leeper
    Elizabeth Vera
    Tito Mendoza
    Kelly Mentges
    Alvina A. Acquaye-Mallory
    Kendra A. Adegbesan
    Lisa Boris
    Eric Burton
    Anna Choi
    Ewa Grajkowska
    Tricia Kunst
    Jason Levine
    Nicole Lollo
    Hope Miller
    Marissa Panzer
    Marta Penas-Prado
    Valentina Pillai
    Lily Polskin
    Jennifer Reyes
    Solmaz Sahebjam
    Macy L. Stockdill
    Brett J. Theeler
    Jing Wu
    Mark R. Gilbert
    Terri S. Armstrong
    Journal of Neuro-Oncology, 2023, 162 : 137 - 145
  • [10] Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC): A multicenter, single arm phase 2 trial (SAKK 06/19).
    Cathomas, Richard
    Spahn, Martin
    Hayoz, Stefanie
    Chiquet, Sabrina
    Schneider, Martina
    Rentsch, Cyrill A.
    Rothschild, Sacha
    Petrausch, Ulf
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS707 - TPS707
123